ArticlePloS one2016
Understanding and Controlling Sialylation in a CHO Fc-Fusion Process.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 39 citations in OpenAlex.
- Gene overexpression reduces inhibitory metabolites to enhance CHO cell growth and IgG1 production.NPJ systems biology and applications · 2026Article
- Effects of sialylated oligosaccharides on the N- and O-glycosylation of etanercept in recombinant CHO cells.Applied microbiology and biotechnology · 2026Article
- Development of a Cellular Membrane Nanovesicle-Based Vaccine Against Porcine Epidemic Diarrhea Virus.Cells · 2026Article
- A strategic approach to multi-omics literature retrieval in next generation mammalian cell bioprocessing.NPJ systems biology and applications · 2025Review
- Impact of DO, agitation, aeration and copper concentration on lactate metabolism and charge heterogeneity for monoclonal antibody production by CHO cells in fed-batch culture.Cytotechnology · 2025Article
- Integrated SegFlow, µSIA, and UPLC for Online Sialic Acid Quantitation of Glycoproteins Directly from Bioreactors.Engineering in life sciences · 2025Article
- Recombinant manufacturing of multispecies biolubricants.bioRxiv : the preprint server for biology · 2024Article
- Development of a miniature bioreactor model to study the impact of pH and DOT fluctuations on CHO cell culture performance as a tool to understanding heterogeneity effects at large-scale.Biotechnology progress · 2022Article
- Immune checkpoint inhibitor-related hepatotoxicity: A review.World journal of gastroenterology · 2021Review
- Impact of iron raw materials and their impurities on CHO metabolism and recombinant protein product quality.Biotechnology progress · 2021Article
- Animal Cell Expression Systems.Advances in biochemical engineering/biotechnology · 2021Article
- CHOmics: A web-based tool for multi-omics data analysis and interactive visualization in CHO cell lines.PLoS computational biology · 2020Article
- Oxidative stress-alleviating strategies to improve recombinant protein production in CHO cells.Biotechnology and bioengineering · 2020Review
- Increased MSX level improves biological productivity and production stability in multiple recombinant GS CHO cell lines.Engineering in life sciences · 2020Article
- Stable Protein Sialylation in Physcomitrella.Frontiers in plant science · 2020Article
- Improvements in protein production in mammalian cells from targeted metabolic engineering.Current opinion in systems biology · 2017Article
- Ponatinib as a Valid Alternative Strategy in Patients with Blast Crisis-Chronic Myeloid Leukemia Not Eligible for Allogeneic Stem Cells Transplantation and/or Conventional Chemotherapy: Report of a Case.Case reports in hematology · 2017Article
- NS0 and CHO cell lines generate distinct quality profiles for non-originator NISTmAbs.Biotechnology progressArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A Chinese hamster ovary (CHO) bioprocess, where the product is a sialylated Fc-fusion protein, was operated at pilot and manufacturing scale and significant variation of sialylation level was observed. In order to more tightly control glycosylation profiles, we sought to identify the cause of variability. Untargeted metabolomics and transcriptomics methods were applied to select samples from the large scale runs. Lower sialylation was correlated with elevated mannose levels, a shift in glucose metabolism, and increased oxidative stress response. Using a 5-L scale model operated with a reduced dissolved oxygen set point, we were able to reproduce the phenotypic profiles observed at manufacturing scale including lower sialylation, higher lactate and lower ammonia levels. Targeted transcriptomics and metabolomics confirmed that reduced oxygen levels resulted in increased mannose levels, a shift towards glycolysis, and increased oxidative stress response similar to the manufacturing scale. Finally, we propose a biological mechanism linking large scale operation and sialylation variation. Oxidative stress results from gas transfer limitations at large scale and the presence of oxygen dead-zones inducing upregulation of glycolysis and mannose biosynthesis, and downregulation of hexosamine biosynthesis and acetyl-CoA formation. The lower flux through the hexosamine pathway and reduced intracellular pools of acetyl-CoA led to reduced formation of N-acetylglucosamine and N-acetylneuraminic acid, both key building blocks of N-glycan structures. This study reports for the first time a link between oxidative stress and mammalian protein sialyation. In this study, process, analytical, metabolomic, and transcriptomic data at manufacturing, pilot, and laboratory scales were taken together to develop a systems level understanding of the process and identify oxygen limitation as the root cause of glycosylation variability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.